GW-842,166X

CAS Number

• 666260-75-9

PubChem CID

• 10253143

ChemSpider

• 8428629

UNII

• VL1I6P2DZ8

GW-842,166X

Identifiers
IUPAC name 2-(2,4-dichloroanilino)-N-(tetrahydropyran-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide
CAS Number	666260-75-9
PubChem CID	10253143
ChemSpider	8428629
UNII	VL1I6P2DZ8
ChEMBL	ChEMBL225411
CompTox Dashboard (EPA)	DTXSID60216786
Chemical and physical data
Formula	C18H17Cl2F3N4O2
Molar mass	449.26 g·mol−1
3D model (JSmol)	Interactive image
SMILES C3COCCC3CNC(=O)c1cnc(nc1C(F)(F)F)Nc2ccc(Cl)cc2Cl
InChI InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27) Key:TWQYWUXBZHPIIV-UHFFFAOYSA-N
(verify)

GW-842,166X is a drug which acts as a potent and selective cannabinoid CB₂ receptor agonist, with a novel chemical structure based on a pyrimidine core. It has potent analgesic, anti-inflammatory and anti-hyperalgesic actions in animal models, but without cannabis-like behavioural effects due to its extremely low affinity for the CB₁ receptor.^[1][2] GSK brought this compound for into 4 clinical trials, two of them related to pain management^[3][4] and the other two related to bio-distributions.^[5][6] The trials were either withdrawn or completed without posting result.